NAV
$42.96
AUM
$1.3B
Expense Ratio
-
Dividend Yield
0.00%
Beta
2.49
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +51.19% | +31.10% | +60.67% | +79.88% | +8.10% | -14.04% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | TWST | Twist Bioscience Corp | 8.56% |
| 2 | CRSP | CRISPR Therapeutics AG | 8.22% |
| 3 | TEM | Tempus AI Inc Class A common stock | 7.78% |
| 4 | PSNL | Personalis Inc | 6.40% |
| 5 | TXG | 10x Genomics Inc Ordinary Shares - Class A | 6.29% |
| 6 | ABSI | Absci Corp | 5.63% |
| 7 | BEAM | Beam Therapeutics Inc | 5.07% |
| 8 | GH | Guardant Health Inc | 4.51% |
| 9 | ILMN | Illumina Inc | 4.48% |
| 10 | NTRA | Natera Inc | 4.11% |
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
Inception Date: 2014-10-31